{"title":"The Efficacy and Safety of Adjustable Intragastric Balloon for Weight Loss: A Systematic Review and Meta-Analysis.","authors":"Chuqi Xia, Yinuo Wang, Guowu Sun, Wanyang Lei, Daoming Liang","doi":"10.1159/000542921","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Adjustable intragastric balloon (aIGB), known as a novel minimally invasive therapy for obesity, provides a sustained alternative for weight loss. Weight loss is achieved by implanting a balloon into the patient's stomach, with the volume of the balloon being adjustable through the injection or extraction of physiological saline. Its key distinction from other intragastric balloons lies in post-implantation volume control. Currently, the efficacy and safety of aIGB have not been well described.</p><p><strong>Methods: </strong>MEDLINE, Embase, and the Cochrane Library were searched for relevant articles. Efficacy and safety of aIGB were evaluated by total body weight loss (TWL) after treatment and severe adverse events.</p><p><strong>Results: </strong>A total of 12 eligible studies with 4,981 patients were included. The average inserting time was 9.9 months, and the pooled mean TWL was 16.4% (95% CI: 0.153-0.175, I2 = 91.2%). The pooled prevalence of patients choosing upward balloon adjustment was 34.2% (95% CI: 0.220-0.485, I2 = 96.5), and all reported additional weight loss with a mean of 6.3 (4.8-9.3) kg. The pooled prevalence of patients choosing downward balloon adjustment was 9.2% (95% CI: 0.065-0.119, I2 = 73.9%), and the pooled prevalence of alleviating intolerance in these patients was 90.8% (95% CI: 0.817-0.974, I2 = 53.4%). The pooled prevalence of intolerance and early removal within 3 months was 5.7% (95% CI: 0.035-0.078, I2 = 79.8%), and the pooled prevalence of stomach ulcer was 1.1% (95% CI: 0.008-0.014, I2 = 5.1%). There was no obvious publication bias detected for these outcomes. Leave-one-out and subgroup analysis demonstrated the results were statistically reliable.</p><p><strong>Conclusion: </strong>aIGB has the ability of significant and sustained weight loss and can effectively manage both intolerance and weight loss plateaus by adjusting the balloon volume during treatment.</p>","PeriodicalId":19414,"journal":{"name":"Obesity Facts","volume":" ","pages":"1-13"},"PeriodicalIF":4.7000,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity Facts","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000542921","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Adjustable intragastric balloon (aIGB), known as a novel minimally invasive therapy for obesity, provides a sustained alternative for weight loss. Weight loss is achieved by implanting a balloon into the patient's stomach, with the volume of the balloon being adjustable through the injection or extraction of physiological saline. Its key distinction from other intragastric balloons lies in post-implantation volume control. Currently, the efficacy and safety of aIGB have not been well described.
Methods: MEDLINE, Embase, and the Cochrane Library were searched for relevant articles. Efficacy and safety of aIGB were evaluated by total body weight loss (TWL) after treatment and severe adverse events.
Results: A total of 12 eligible studies with 4,981 patients were included. The average inserting time was 9.9 months, and the pooled mean TWL was 16.4% (95% CI: 0.153-0.175, I2 = 91.2%). The pooled prevalence of patients choosing upward balloon adjustment was 34.2% (95% CI: 0.220-0.485, I2 = 96.5), and all reported additional weight loss with a mean of 6.3 (4.8-9.3) kg. The pooled prevalence of patients choosing downward balloon adjustment was 9.2% (95% CI: 0.065-0.119, I2 = 73.9%), and the pooled prevalence of alleviating intolerance in these patients was 90.8% (95% CI: 0.817-0.974, I2 = 53.4%). The pooled prevalence of intolerance and early removal within 3 months was 5.7% (95% CI: 0.035-0.078, I2 = 79.8%), and the pooled prevalence of stomach ulcer was 1.1% (95% CI: 0.008-0.014, I2 = 5.1%). There was no obvious publication bias detected for these outcomes. Leave-one-out and subgroup analysis demonstrated the results were statistically reliable.
Conclusion: aIGB has the ability of significant and sustained weight loss and can effectively manage both intolerance and weight loss plateaus by adjusting the balloon volume during treatment.
期刊介绍：
''Obesity Facts'' publishes articles covering all aspects of obesity, in particular epidemiology, etiology and pathogenesis, treatment, and the prevention of adiposity. As obesity is related to many disease processes, the journal is also dedicated to all topics pertaining to comorbidity and covers psychological and sociocultural aspects as well as influences of nutrition and exercise on body weight. The editors carefully select papers to present only the most recent findings in clinical practice and research. All professionals concerned with obesity issues will find this journal a most valuable update to keep them abreast of the latest scientific developments.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
